Expertise in
5
conditions

Jinming M. Liu

Shanghai, CN 
Expertise in
5
conditions
Shanghai, CN 

Overview

Jinming Liu practices practicing medicine in Shanghai, China.

Liu is highly rated in 5 conditions, according to our data. Their clinical expertise encompasses Pulmonary Hypertension, Pulmonary Embolism, Hypertension, Endoscopy, and Angioplasty.

They are actively involved in clinical research, co-authoring 108 peer reviewed articles and participating in 4 clinical trials.

Locations

Shanghai, China
Other Locations
MOE Key Laboratory Of Geriatric Diseases And Immunology, Suzhou, China
Yicheng, 214200, China
The Anhui Provincial Key Laboratory Of Biodiversity Conservation And Ecological Security In The Yangtze River Basin, Wuhu, 241000, China
Wuxi, China
Hangzhou, 310014, China
Xuzhou, 211009, China
Key Laboratory Of Advanced Marine Materials, Ningbo, 315201, China
120 Su Zhi Road, Sucheng District, Suqian, 223800, China
Jiangsu Province Key Laboratory Of Oral Diseases, Nanjing, 210029, China
507 Zhengmin Road, Yangpu, 200433, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label Extension Trial to Evaluate the Safety of Continued Therapy With Subcutaneous Remodulin® in Subjects With Pulmonary Arterial Hypertension Who Completed Study CVT-CV-003
An Open-Label Extension Trial to Evaluate the Safety of Continued Therapy With Subcutaneous Remodulin® in Subjects With Pulmonary Arterial Hypertension Who Completed Study CVT-CV-003
Enrollment Status: Withdrawn
Publish Date: May 09, 2017
Intervention Type: Drug
Study Phase: Phase 4
A 16-Week, Open-Label, Multi-Center, Parallel, Randomized Controlled Study to Compare the Safety, Tolerability, Pharmacokinetics and Efficacy of Slow and Rapid Dose Titration Regimens of Subcutaneous Remodulin Therapy in Subjects With Pulmonary Arterial Hypertension
A 16-Week, Open-Label, Multi-Center, Parallel, Randomized Controlled Study to Compare the Safety, Tolerability, Pharmacokinetics and Efficacy of Slow and Rapid Dose Titration Regimens of Subcutaneous Remodulin Therapy in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Withdrawn
Publish Date: May 09, 2017
Intervention Type: Drug
Study Phase: Phase 4
View 3 Less Clinical Trials

108 Total Publications

Combined treatment of spinal cord injury using channeled Porous-GelMA scaffold loaded with genetically engineered MSCs expressing inducible ChABC and constitutive BDNF.
Combined treatment of spinal cord injury using channeled Porous-GelMA scaffold loaded with genetically engineered MSCs expressing inducible ChABC and constitutive BDNF.
Journal: Frontiers in bioengineering and biotechnology
Published: March 25, 2026

Frequently Asked Questions about Jinming M. Liu

Is Jinming M. Liu a top-rated expert for Pulmonary Hypertension?

MediFind is an objective health platform that identifies experts based on real-world data. Jinming M. Liu is classified as an Distinguished expert for Pulmonary Hypertension, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jinming M. Liu participate in research or clinical trials?

Yes. Jinming M. Liu has published 108 articles and abstracts on conditions like Pulmonary Hypertension. You can view a list of Jinming M. Liu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Liu's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile